🎉 M&A multiples are live!
Check it out!

Rocket Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Rocket Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Rocket Pharmaceuticals Overview

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.


Founded

1999

HQ

United States of America
Employees

299

Financials

LTM Revenue $12.7M

LTM EBITDA -$240M

EV

$283M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Rocket Pharmaceuticals Financials

Rocket Pharmaceuticals has a last 12-month revenue of $12.7M and a last 12-month EBITDA of -$240M.

In the most recent fiscal year, Rocket Pharmaceuticals achieved revenue of n/a and an EBITDA of -$247M.

Rocket Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Rocket Pharmaceuticals valuation multiples based on analyst estimates

Rocket Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$237M -$247M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$222M -$246M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Rocket Pharmaceuticals Stock Performance

As of April 15, 2025, Rocket Pharmaceuticals's stock price is $6.

Rocket Pharmaceuticals has current market cap of $630M, and EV of $283M.

See Rocket Pharmaceuticals trading valuation data

Rocket Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$283M $630M XXX XXX XXX XXX $-2.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Rocket Pharmaceuticals Valuation Multiples

As of April 15, 2025, Rocket Pharmaceuticals has market cap of $630M and EV of $283M.

Rocket Pharmaceuticals's trades at 22.4x LTM EV/Revenue multiple, and -1.2x LTM EBITDA.

Analysts estimate Rocket Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Rocket Pharmaceuticals and 10K+ public comps

Rocket Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $283M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.1x XXX XXX XXX
P/E -2.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Rocket Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Rocket Pharmaceuticals Valuation Multiples

Rocket Pharmaceuticals's NTM/LTM revenue growth is 468%

Rocket Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Rocket Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Rocket Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Rocket Pharmaceuticals and other 10K+ public comps

Rocket Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 5% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Rocket Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Rocket Pharmaceuticals M&A and Investment Activity

Rocket Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Rocket Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Rocket Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Rocket Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Rocket Pharmaceuticals

When was Rocket Pharmaceuticals founded? Rocket Pharmaceuticals was founded in 1999.
Where is Rocket Pharmaceuticals headquartered? Rocket Pharmaceuticals is headquartered in United States of America.
How many employees does Rocket Pharmaceuticals have? As of today, Rocket Pharmaceuticals has 299 employees.
Who is the CEO of Rocket Pharmaceuticals? Rocket Pharmaceuticals's CEO is Dr. Gaurav Shah, M.D..
Is Rocket Pharmaceuticals publicy listed? Yes, Rocket Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Rocket Pharmaceuticals? Rocket Pharmaceuticals trades under RCKT ticker.
When did Rocket Pharmaceuticals go public? Rocket Pharmaceuticals went public in 2015.
Who are competitors of Rocket Pharmaceuticals? Similar companies to Rocket Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Rocket Pharmaceuticals? Rocket Pharmaceuticals's current market cap is $630M
What is the current revenue of Rocket Pharmaceuticals? Rocket Pharmaceuticals's last 12-month revenue is $12.7M.
What is the current EBITDA of Rocket Pharmaceuticals? Rocket Pharmaceuticals's last 12-month EBITDA is -$240M.
What is the current EV/Revenue multiple of Rocket Pharmaceuticals? Current revenue multiple of Rocket Pharmaceuticals is 22.4x.
What is the current EV/EBITDA multiple of Rocket Pharmaceuticals? Current EBITDA multiple of Rocket Pharmaceuticals is -1.2x.
Is Rocket Pharmaceuticals profitable? Yes, Rocket Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.